NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMSNewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on discovering and developing innovative therapies for cardiovascular diseases. Established with a research-oriented approach, it aims to address unmet medical needs through advanced science and targeted treatments. The company is listed on the stock exchange under the ticker NAMS and operates with a focus on improving patient outcomes in the cardiovascular space.
Company News
NewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-...
NewAmsterdam Pharma announced that company management will participate in investor conferences including the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company is developing obicetrapib, an oral CETP inhibitor, for LDL-C lowering in cardiovascular dis...
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 50,400 share options and 15,400 restricted stock units to five new non-executive employees. The options have an exercise price of $28.43 per share with four-year vesting, while RSUs vest over three years. These grants were made under the 2024 Inducement Plan in compliance ...
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 15,000 share options and 3,200 restricted stock units to two non-executive new hires. The options have an exercise price of $32.81 per share with four-year vesting, while RSUs vest over three years. Both grants were made under the 2024 Inducement Plan in compliance with Na...
NewAmsterdam Pharma announced that its CFO Ian Somaiya and EVP of Investor Relations Matthew Philippe will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovas...
